Related Articles
Response to alectinib after one year of discontinuation of crizotinib in anaplastic lymphoma kinase-positive non-small-cell lung cancer: A case report
Response to erlotinib in a patient with lung adenocarcinoma harbouring the EML4-ALK translocation: A case report
Primary signet‑ring cell carcinoma of the lung treated with crizotinib: A case report
EML4-ALK translocation is associated with early onset of disease and other clinicopathological features in Chinese female never-smokers with non-small-cell lung cancer
Long‑term complete response in a patient with postoperative recurrent ALK‑rearranged lung adenocarcinoma treated with crizotinib: A case report